The classical hyperbolic Michaelis-Menten equation has long been used to characterize the in vitro kinetics of enzyme-catalyzed reactions. More recently, cytochrome P450 (P450) catalyzed enzymatic reactions that exhibit sigmoidal kinetics have been described in the literature. Notable examples of this type of kinetic behavior include P450 3A4 catalyzed oxidation of testosterone (Ueng et al., 1997) and carbamazepine (Korzekwa et al., 1998) . Rate versus substrate concentration profiles for sigmoidal kinetics have a characteristic initial lag at lower concentrations and result in characteristic curved Eadie-Hofstee plots. Such kinetic behavior is often attributed to autoactivation of enzymes that occurs with increasing substrate concentrations and are often described empirically using the Hill Equation (Houston and Kenworthy, 2000) . Models involving the binding of multiple substrate molecules to the enzyme active site have been proposed to provide a mechanistic description of autoactivation kinetics (Ueng et al., 1997; Korzekwa et al, 1998) More recently, examples of similar kinetic phenomenon have been reported for UDPglucuronosyltransferases (UGT). The formation of estradiol-3-glucuronide, a UGT 1A1 selective reaction, was observed to have a better fit to the Hill equation in both human liver microsomes and recombinant UGT 1A1 (Fischer et al., 2000; Soars et al., 2003) . Similar autoactivation kinetics have also been observed for the formation of the glucuronic acid conjugate of acetaminophen in human liver microsomes, and in recombinant UGT1A1 and UGT1A9 (Fischer et al., 2000; Court et al., 2001) . The mechanism of autoactivation kinetics observed for UGT's is currently unknown.
Valproic acid (2-propylpentanoic acid, VPA) is a broad spectrum anticonvulsant with a unique branched-chain fatty acid structure (Davis et al., 1994) . Previous studies in sheep, demonstrated that VPA was primarily eliminated in this species via glucuronidation with ~ 70-80 % of an administered intravenous dose recovered in urine as VPA-glucuronide (VPAG, Wong et al., 2001) . The appearance of VPAG in sheep urine appeared to be formation rate-limited rather This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on May 11, 2007 as DOI: 10.1124 at ASPET Journals on April 1, 2017 dmd.aspetjournals.org Downloaded from than excretion rate-limited. Based upon these properties, we were able to assess the in vivo apparent V max and K m of VPA glucuronidation in sheep using either the disappearance of the parent compound from plasma or the excretion rate of VPAG in urine (Wong et al., 2001) . In our preliminary studies examining VPAG formation in sheep liver microsomes, characteristics of autoactivation kinetics were observed (Kumar and Wong, unpublished results). As mentioned, sigmoidal kinetics has been previously observed in vitro for both P450 and UGT catalyzed reactions. However, the in vivo relevance of sigmoidal/autoactivation kinetics has never been clearly demonstrated. Valproic acid is unique in that high doses of the compound can be administered such that saturation of its elimination (glucuronidation) occurs in vivo, thus allowing for full characterization of kinetic parameters for its metabolism in vivo. This ability to characterize VPA glucuronidation kinetics in vivo provided a unique opportunity for us to investigate whether the autoactivation kinetics for VPA glucuronidation can be observed in vitro in liver microsomes and, if so, whether this would translate to the in vivo situation. Thus, the objective of the studies described in this manuscript was to investigate the occurrence of sigmoidal/autoactivation kinetics for VPA glucuronidation in vitro and in vivo in sheep.
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METHODS
In Vivo Animal Experiments
Five Dorset Suffolk cross-bred ewes, with a body weight of 61.9 ± 7.3 kg (mean ± S.D.) were surgically prepared with a minimum of three days prior to experimentation. Polyvinyl catheters (Dow Corning, Midland, MI) were implanted in a femoral artery and vein (catheter i.d. 1.02 mm and o.d. 2.16 mm) as described by Kumar et al. (1999) . Briefly, animals were administered an iv bolus of VPA (Sodium Valproate, Sigma Chemical Co., St. Louis, MO) at a dose of 100 mg/kg body weight over 1 min via the femoral vein. Blood samples (~3 ml) were collected via the femoral artery at 5, 15, 30, 45 min, and 1, 2, 4, 6, 9, 12, 15, 24, 36, 48, 60 Cumulative urine samples were collected via a Foley  bladder catheter for the following time intervals: 0-2 , 2-4, 4-6, 6-9, 9-12, 12-15, 15-24, 24-36, 36-48, 48-60, and 60-72 hours post dose.
Plasma and urine samples were stored frozen at -20°C until the time of analysis. All studies were approved by the University of British Columbia Animal Care Committee, and the procedures performed on sheep conformed to the guidelines of the Canadian Council on Animal Care.
Unbound plasma concentrations of VPA were determined ex vivo in all adult sheep plasma samples using an ultrafiltration procedure as described by Wong et al. (2001) . Concentrations of VPA and its metabolites in plasma ultrafiltrate and urine were measured simultaneously using an established gas chromatographic-mass spectrometric (GC-MS) analytical method (Yu et al., 1995) .
The variability and bias of all analytes measured using this analytical method was determined to be (Yu et al., 1995) . VPA and metabolite calibration and quality control standards as well as control (blank) biological fluid samples were run with each batch of study samples. Concentrations of the VPAG in urine were determined as described by Wong et al. (2001) .
In Vitro Valproic Acid Glucuronidation Kinetics
The glucuronidation kinetics of valproic acid were examined in pooled sheep liver microsomes (pool of 10) (Xenotech LLC, Lenexa, KS). The kinetics of VPA glucuronidation was determined under the following incubation conditions: VPA (5 to 640 µM), 0.5 mg/ml microsomal protein, 2.5 mM MgCl 2 , 5 mM sacchorlactone, alamethacin (10 µg/mg protein), and 3 mM UDPGA (Sigma-Aldrich Co., St. Louis, MO) in 100 mM phosphate buffer (pH 7.5).
Total incubation volume was 200 µL. All contents of each incubation, with the exception of UDPGA, were pre-incubated for 5 minutes at 37°C. Following the pre-incubation period, reactions were initiated by the addition of UDPGA. Reactions were terminated at 20 minutes by the addition of 200 µL of ice-cold acetonitrile containing the internal standard (diclofenac at 2 µM final concentration; Sigma-Aldrich Co., St. Louis, MO) followed by thorough vortexmixing. The resulting samples were centrifuged at 2000 g for 10 minutes at 4°C and 10 µL of the supernatant was injected into a liquid chromatograph coupled with a tandem mass spectrometer (LC-MS) for quantitation of VPAG. All reactions were performed in triplicate. In preliminary experiments, reactions performed under the described conditions were linear with respect to both microsomal protein concentration and incubation time (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. column (50 mm x 2 mm ID, Waters Corporation, Milford, MA). The mobile phase consisted of (A) 95% water and 5% acetonitrile with 5 mM ammonium acetate and (B) 95% acetonitrile and 5% water with 5 mM ammonium acetate. The LC pumps were programmed to pump 25% B from 0-1 min, followed by an increase to 90% B from 1-2 min, a hold at 90% B from 2-4 min, and a return to 25% B for column re-equilibration. The HPLC flow rate was 0. 
Determination of Unbound Valproic Acid in Sheep Liver Microsomes
Unbound fraction of VPA in pooled sheep liver microsomes under in vitro incubation conditions was determined by ultracentrifugation using 700 µM), 0.5 mg/mL microsomal protein, 2.5 mM MgCl 2 , alamethicin (10 µg/mg microsomal protein), and 5 mM saccharolactone in 100 mM phosphate buffer (pH 7.4). The total incubation volume was 4 mL. After an incubation period of 30 min at 37°C, 1 mL aliquot of each sample was transferred in triplicate to centrifuge tubes (11 x 34 mm PC tubes, Beckman Coulter Inc., Fullerton, CA) and samples underwent centrifugation at 100,000 rpm for 3 hrs using an Optima TLX ultracentrifuge (Beckman Coulter Inc., Fullerton, CA). Radioactivity content was determined in the supernatant from the samples after centrifugation and in the original microsomal incubation prior to centrifugation using a Tri-Carb 3100 TR liquid scintillation analyzer (Perkin-Elmer, Boston, MA). The fraction unbound was calculated as the ratio of the average radioactivity measured in the supernatant layers (unbound fraction) to that in the initial microsomal incubate prior to centrifugation.
Pharmacokinetic and Enzyme Kinetic Analyses
In vivo This article has not been copyedited and formatted. The final version may differ from this version. (Wagner, 1993) . Mean estimates for parameters are presented as a mean ± SD.
In vivo estimates of kinetic parameters for VPA glucuronidation from urinary excretion data were determined by fitting v (urinary excretion rate of the glucuronide metabolite) vs. C mid (unbound VPA plasma concentration at the midpoint of the urine collection interval) data to the Hill equation
. C mid and v are as defined above, V max app is the apparent maximal formation rate of VPAG, S 50 app is the substrate concentration resulting in 50% of V max app , and n is the Hill coefficient. The fitting to the Hill equation rather than the classical MichaelisMenten equation was determined based upon the distinct shape of the Eadie-Hofstee plots, and by minimization of the sum of squares of residuals and the standard error of parameter estimates when data were fitted to the Hill equation. Data sets were individually fit for each animal using GraphPad Prism V4.02 (GraphPad Software Inc., San Diego, CA).
Rate of VPAG formation vs. VPA incubation concentration from in vitro enzyme kinetic experiment using pooled sheep liver microsomes were fit to the Hill equation using GraphPad Prism V4.02 as described above for the in vivo urine data. VPA incubation concentration substituted for C mid when fitting the data from the in vitro experiment.
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RESULTS
Urinary recovery of VPA Dose
The recovery of the VPA and its metabolites in urine following a 100 mg/kg intravenous dose is presented in Table 1 . Essentially, the entire VPA dose was recovered in urine from all five animals.
VPAG was the main metabolite found in urine accounting for approximately 80% of the entire dose. Following the glucuronide metabolite, unchanged VPA accounted for the second largest portion of the administered dose recovered in urine (~7%). All other metabolites combined, on average, accounted for <10% of the administered dose (Table 1) . Table 2 . These resulting parameters are hybrid constants that are largely reflective of overall metabolic elimination. These estimates are comparable to estimates generated using VPAG urinary excretion data (Table 2) 
In Vivo
Urinary Excretion Data
A condition for estimating the apparent kinetic parameters of VPA glucuronidation using urine data is that the appearance of VPAG in urine is formation, as opposed to elimination rate-limited (Gilbaldi and Perrier, 1982) . Metabolites demonstrating formation rate-limited urinary excretion exhibit plasma concentration vs time profiles that decline in parallel to those of the parent compound (Houston, 1986) . In previous investigations with VPA using pregnant sheep, we attempted to measure the plasma concentrations of the VPAG by subjecting the samples to hydrolysis and subtracting the concentrations of the unconjugated VPA. However, it was evident from these attempts that the plasma concentrations of the VPA glucuronide conjugate were substantially lower than those of the parent and could not be reliably measured by our difference-based analytical approach (S. Kumar, unpublished results). This is consistent with the likely formation rate-limited urinary excretion of the VPA glucuronide. Furthermore, in the absence of a plasma profile, a plot of urinary excretion rate of VPAG versus t mid (i.e., time at the midpoint of the urine collection interval) can be used to estimate the slope of the terminal decline / half-life of the VPAG in plasma (Gibaldi and Perrier, 1982) . Figure 2 is a plot of mean urinary excretion rate of VPAG vs t mid , together with a mean unbound VPA plasma concentration-time profile. The parallel decline of these two plots is also consistent with the urinary excretion of VPAG being formation rate-limited. This is consistent with our previous observation of Table 2 . The in vitro estimates of S 50 app and n were comparable to those estimated in vivo (Table 2) .
Enzyme Kinetics of VPA Glucuronidation in Sheep Liver Microsomes
Unbound fraction of VPA in sheep liver microsomes at VPA concentrations of 5 and 700 µM were 93 and 98%, respectively, suggesting negligible nonspecific binding in microsomes over the VPA concentration range used in our in vitro studies (5 to 640 µM). Hence, no correction was made for the binding of VPA to liver microsomal protein.
This article has not been copyedited and formatted. The final version may differ from this version. , 2000) . The exact mechanistic explanation for various aspects of sigmoidal kinetics has yet to be fully elucidated. Early observations of sigmoidal kinetics for xenobiotic metabolizing enzymes were mostly in human liver microsomal and cDNA-expressed systems (Ueng et al., 1997; Korzekwa et al., 1998) . Later work using dextromethorphan by Witherow and Houston (1999) demonstrated that sigmoidal kinetics could also be observed in hepatocytes. More recently, reports of similar kinetic phenomenon have been reported for UDP-glucuronosyltransferases (UGT) in both human liver microsomes and recombinant systems (Fischer et al., 2000; Soars et al., 2003; Fischer et al., 2000; Court et al., 2001 ). However, the in vivo relevance of autoactivation kinetics has never been clearly demonstrated.
Valproic acid presents a unique tool to examine the relevance of sigmoidal or autoactivation kinetics in vivo. Studies using rat hepatocytes over a wide concentration range (100 nM to 1.8 mM)
indicate that the uptake of VPA into hepatocytes is linear, rapid, and does not involve carrier mediated transport (Booth et al., 1996) . We have demonstrated that the excretion of VPAG in urine is formation rather then excretion rate-limited in the current study and in a previous study (Wong et al., 2001) . Based upon these two properties, the in vivo excretion kinetics of VPAG are reflective of enzymatic processes involved in its formation rather than transport and/or distribution phenomenon. In a previous study, VPAG urinary excretion data from multiple in vivo experiments were pooled to generate a single rate versus substrate concentration plot (VPAG urinary excretion rate vs C mid ) (Wong et al., 2001 ). This profile was fitted to the Michaelis-Menten equation in order to provide in vivo estimates of apparent V max and K m for VPA glucuronidation. The sigmoidal features of rate-substrate concentration plots in our previous study were likely masked as a result of the data pooling process. Eadie-Hofstee plots from individual sheep are presented for the current study ( Figure 3 ) and clearly display the "curved" shape that is characteristic of sigmoidal or autoactivation kinetics.
Since VPA is almost entirely eliminated via glucuronidation (Table 1) , the disappearance of the unbound parent compound from plasma should be reflective of kinetic processes governing glucuronidation. VPA is a low clearance drug in sheep such that its total body clearance approximates f u (unbound fraction of VPA) × Cl int (intrinsic clearance) (Wilkinson and Shand, 1975) . Thus, the clearance of unbound VPA is equal to its Cl int . Cl int is described by equation 3 Characterization of VPA's nonlinear elimination using Michealis-Menten kinetics required the simultaneous fitting of unbound plasma concentration-time profiles from three doses (50, 100, and 250 mg/kg; Wong et al., 2001 ) in contrast to the single dose data (100 mg/kg) being fitted in the current study. The doses used in the previous study spanned a range over which metabolic saturation was obvious from the observed decreases in unbound VPA clearance with increases in dose (Wong et. al., 2001 ).
Our in vitro experiment in pooled sheep liver microsomes demonstrates that the glucuronidation of valproic acid is characterized by sigmoidal or autoactivation kinetics and provides an explanation for our in vivo observations. To our knowledge, this is the first report of in vitro VPA glucuronidation exhibiting autoactivation kinetics. Sigmoidal kinetics that are observed in vitro may result as a consequence of in vitro incubation conditions where substrate depletion occurs due to non-specific binding to incubation matrix or an overabundance of enzyme. At the lowest concentration of VPA tested in our study (5 µM), ~2% of the substrate was converted to the glucuronide conjugate. In addition, non-specific VPA microsomal binding appeared to be negligible in the concentration range over which VPA glucuronidation kinetics were assessed. Based upon these conditions, our observations of sigmoidal kinetics in vitro are likely not an experimental artefact and are related to characteristic enzyme-substrate interactions.
Reports of enhanced rates of glucuronidation in humans at high doses of VPA (1000 mg) have been previously described in literature (Granneman et al., 1984) . These enhanced rates could glucuronidation would be more difficult to fully characterize in humans as doses normally administered are far less than those employed in our current study.
To our knowledge, the current study is the first clear demonstration of the occurrence of autoactivation kinetics in vivo in any species. Since the uptake of VPA into hepatocytes has been shown to be rapid and linear over a wide concentration range (Booth et al., 1996) Mean ± SD 7.0 ± 1.6 78.7 ± 5.6 9.3 ± 1.9 95.0 ± 6.7
* includes the following VPA metabolites; 2-n-propyl-2-pentenoic acid, 2-n-propyl-3-pentenoic acid, 2-npropyl-4-pentenoic acid, 2-n-propyl-3-oxopentanoic acid, 2-n-propyl-4-oxopentanoic acid, 3-hydroxy VPA, 4-hydroxy VPA, 5-hydroxy VPA, 2-propylsuccinic acid, 2-propylglutaric acid.
This article has not been copyedited and formatted. The final version may differ from this version. Mean ± SD 2.63 ± 0.33 118 ± 53 2.06 ± 0.47 2.10 ± 0.75 117 ± 56 1.34 ± 0.14 a Estimated from fitting unbound VPA plasma concentration-time profiles to a 2-compartment model with elimination characterized by the Hill equation (Figure 1 ) b Estimated from fitting plots of valproic acid-glucuronide urinary excretion rate of vs. unbound VPA plasma concentrations to the Hill equation.
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